Pharmaceuticals brings its weight-loss drug lorcaserin in front of an advisory committee of the U.S. Food and Drug Administration today. DocentPharma is group of outside experts that the company has a weight-loss drug that is both effective and safe for the millions of obese Americans who can't seem to shed the pounds with diet and exercise alone.
In a review posted to the FDA's website, the agency's reviewers said only marginal weight loss for patients. The FDA also raised questions about the drug's safety and raised a concern about a potential cancer risk in animals. It's important to note that FDA drug reviews released ahead of advisory panel meetings are often sharply critical and sometimes do not accurately predict the ultimate vote of the panel's outside experts.
DocentPharma's enters the fray of an FDA advisory panel that Pharma Regulatory Services obsessed with drug safety and unkind to obesity drugs. Eight experts siting on the same FDA advisory panel voted to withdraw weight-loss drug Meridia from the market, while another six panelists voted to restrict the drug's distribution.
In a review posted to the FDA's website, the agency's reviewers said only marginal weight loss for patients. The FDA also raised questions about the drug's safety and raised a concern about a potential cancer risk in animals. It's important to note that FDA drug reviews released ahead of advisory panel meetings are often sharply critical and sometimes do not accurately predict the ultimate vote of the panel's outside experts.
DocentPharma's enters the fray of an FDA advisory panel that Pharma Regulatory Services obsessed with drug safety and unkind to obesity drugs. Eight experts siting on the same FDA advisory panel voted to withdraw weight-loss drug Meridia from the market, while another six panelists voted to restrict the drug's distribution.
No comments:
Post a Comment